mRNA Technology Newsletter
Issue #30March 30, 20267 studies

Freeze-dried mRNA vaccines stay stable for 4 months at fridge temperature

This week brought major breakthroughs in making mRNA vaccines more accessible worldwide, plus advances in targeting cancer cells and understanding how our immune systems respond to these revolutionary therapies.

๐ŸงŠ Freeze-drying could eliminate cold-chain requirements for mRNA vaccines

  • Scientists developed freeze-dried mRNA vaccine formulations that remained stable and functional for 4 months at refrigerator temperature (4ยฐC), compared to current vaccines that require ultra-cold storage

  • The best-performing formulation used 20% sucrose with Tris buffer, maintaining over 90% encapsulation efficiency and preserving particle size around 200 nm after reconstitution

  • At room temperature (20ยฐC), the formulations showed progressive destabilization over 6 months, but one sucrose-based version retained acceptable stability

Why it matters: Current mRNA vaccines require expensive ultra-cold storage (-70ยฐC), limiting global distribution especially in low-resource settings. This freeze-drying approach could make mRNA vaccines as easy to store and distribute as traditional vaccines.

Top 20% journal ๐Ÿ”— Vaccines Journal Article ๐Ÿ—“๏ธ Mar 27

Key Findings

๐ŸŽฏ New enzyme method detects thousands of RNA modifications with enhanced precision

  • Researchers developed ELAP-seq, which uses a naturally occurring enzyme from an ancient microorganism to tag pseudouridine modifications in RNA with single-nucleotide resolution

  • The method identified thousands of candidate pseudouridine sites in human HeLa and HEK 293T cells with markedly enhanced signal-to-noise ratio

  • Unlike previous techniques, this approach reduces sequencing and computational demands while providing high sensitivity and specificity

๐Ÿ’ก This tool could accelerate research into how RNA modifications influence disease and drug responses.
๐Ÿฅˆ Top 2% journal ๐Ÿ”— Nature communications Journal Article ๐Ÿ—“๏ธ Mar 24

๐Ÿ”ฌ Circular RNA emerges as more stable vaccine platform than linear mRNA

  • Circular RNA vaccines demonstrated sustained antigen availability and robust immune responses due to their covalently closed structure, which enhances molecular stability compared to linear mRNA

  • These vaccines showed flexibility in multivalent designs and targeted delivery strategies that support germinal center reactions and neutralizing antibody generation

  • In cancer applications, circular RNA vaccines focused on inducing potent CD8+ T cell immunity and enabling combination immunotherapy approaches

๐Ÿ’ก Circular RNA could offer longer-lasting vaccine protection with potentially fewer booster shots needed.
Top 20% journal ๐Ÿ”— Vaccines Review ๐Ÿ—“๏ธ Mar 27

๐Ÿงฌ Single-component delivery system simplifies mRNA vaccine manufacturing

  • Scientists created ionizable amphiphilic Janus dendrimers (IAJD) that self-assemble into a one-component delivery system, eliminating the need for complex four-component lipid nanoparticles

  • IAJD97 formulated with norovirus mRNA efficiently delivered vaccines to spleen and lymph nodes, demonstrating the potential for rapid global distribution during pandemics

  • This single-component system simplifies synthesis, reduces development complexity, and could enable faster vaccine deployment

๐Ÿ’ก Simpler vaccine formulations could dramatically reduce manufacturing costs and speed up pandemic responses.
๐Ÿฅˆ Top 2% journal ๐Ÿ”— Science advances Journal Article ๐Ÿ—“๏ธ Mar 27

๐Ÿ’‰ Low-dose multivalent COVID vaccines outperform high-dose single-strain versions

  • A low-dose trivalent mRNA vaccine elicited broadly cross-reactive antibodies against various SARS-CoV-2 variants at higher levels than a high-dose monovalent vaccine

  • Combining low-dose trivalent mRNA with spike proteins from multiple variants further increased cross-reactive antibody levels and neutralizing activity

  • Co-administering low doses of SARS-CoV-2 spike mRNA with inactivated influenza vaccines significantly enhanced immunogenicity and efficacy against influenza

๐Ÿ’ก Lower doses targeting multiple variants could provide broader protection while reducing side effects.
Top 30% journal ๐Ÿ”— Virology Journal Article ๐Ÿ—“๏ธ Mar 27

๐Ÿงช Engineered lipid nanoparticles target lymph nodes while avoiding liver

  • New aromatic bioreducible ionizable lipids created LNPs that accumulate in and transfect lymph nodes while minimizing off-target liver accumulation

  • These aromatic LNPs induced stronger antigen-specific immune responses, increased effector memory T cell generation, and decreased terminal effector T cell generation in a SARS-CoV-2 vaccine study

  • The particles were strongly retained at injection sites and induced low levels of systemic inflammatory cytokines

๐Ÿ’ก Better-targeted delivery could improve vaccine effectiveness while reducing unwanted side effects.
๐Ÿฅ‡ Top 1% journal ๐Ÿ”— Journal of the American Chemical Society Journal Article ๐Ÿ—“๏ธ Mar 24

๐Ÿ”ฌ Real-time monitoring system tracks mRNA production during manufacturing

  • Scientists developed a Raman spectroscopy system that simultaneously monitors ATP, CTP, GTP, UTP, and mRNA concentrations during in vitro transcription with prediction accuracy of Rยฒ 0.82-0.99

  • The method achieved relative errors of 4%-13%, comparable to reference offline assays (10%-12%), and worked across different mRNA sequences without recalibration

  • This real-time monitoring could support transition toward continuous processing and automated manufacturing systems

๐Ÿ’ก Real-time quality control could make mRNA vaccine manufacturing more efficient and reliable.
Top 20% journal ๐Ÿ”— Biotechnology and bioengineering Journal Article ๐Ÿ—“๏ธ Mar 24

Implications

These advances collectively address mRNA vaccines' biggest challenges: storage requirements, manufacturing complexity, and delivery precision. From freeze-dried formulations that work at fridge temperature to single-component delivery systems and real-time manufacturing monitoring, the field is rapidly solving the practical barriers that limit global vaccine access and effectiveness.

Studies in this issue

Primary sources used for this newsletter.

  1. Using enzymes to map pseudouridine changes across all RNA transcripts
    key findingNature communications2026-03-24PMID 41872172
  2. Special mRNA lipid nanoparticles that avoid the liver target lymph nodes and trigger strong immune responses
    key findingJournal of the American Chemical Society2026-03-24PMID 41873855
  3. Real-Time Tracking of mRNA Production in the Lab Using Raman Spectroscopy
    key findingBiotechnology and bioengineering2026-03-24PMID 41872667